drugset
drugset / Trial / NCT02434965

Autologous Cord Blood and Human Placental Derived Stem Cells in Neonates With Severe Hypoxic-Ischemic Encephalopathy

NCT02434965 ↗

Phase 2 Withdrawn New York Medical College Celgene Corporation · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate the safety and effectiveness of autologous human placental-derived stem cells (HPDSC) in combination with autologous cord blood in neonates with severe hypoxic-ischemic encephalopathy.

Timeline

Start
2019-12
Primary completion
2021-01
Completion
2022-01

Drugs

EvaluationDrugModalityDoseRoute
Subject HPDSC Cell therapy — Intravenous
Subject Influenza Virus Vaccine Vaccine — Intravenous

Indications

brain hypoxia - ischemia